This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Cosylab launches PlanOne particle...
Tech product launch

Cosylab launches PlanOne particle therapy system

Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of PlanOne by Cosylab is expected to positively impact the medical technology market by introducing an advanced particle therapy planning system. This could lead to increased competition and innovation in the radiation oncology sector, potentially benefiting patients and healthcare providers.

Medical Technology Software
Event Summary

Cosylab, a software and control systems company based in Ljubljana, Slovenia, has commercially launched PlanOne, a new treatment planning system for particle therapy. PlanOne offers physics-accurate, radiobiologically informed planning and a unified clinical workflow, and has received FDA 510(k) clearance. Mark Plesko, CEO of Cosylab, stated that PlanOne was developed based on feedback from medical physicists and clinical teams, focusing on physics accuracy, clinical confidence, and a platform for future growth with AI and adaptive workflows. The system is built on a GPU-accelerated Monte Carlo dose engine and provides comprehensive user-defined robust optimization, analysis, and evaluation. PlanOne integrates with existing oncology information systems, aiming to preserve established workflows and reduce data migration needs.

Entities Involved
priv
Cosylab
Cosylab launched PlanOne, a new treatment planning system for particle therapy, which is expected to enhance its market position in radiation oncology.
Importance 100.0 Sentiment 70.0
oth
PlanOne
PlanOne is a new treatment planning system for particle therapy launched by Cosylab, offering physics-accurate planning and a unified clinical workflow.
Importance 90.0 Sentiment 70.0
per
Mark Plesko
As CEO of Cosylab, Mark Plesko announced the commercial launch of PlanOne and highlighted its development based on clinical feedback.
Importance 70.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration provided 510(k) clearance for PlanOne, indicating its approval for commercial launch.
Importance 40.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.